Back to search results

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Non-small Cell Lung Cancer Stage IV · Non-small Cell Lung Cancer Recurrent

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Washington University School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Giordano Fabricio Cittolin Santos, MD, PhD) · cgiordano@wustl.edu · 314-273-4731
    Contact: Principal Investigator (Giordano Fabricio Cittolin Santos, MD, PhD)
    Daniel Morgensztern, MD (Sub-investigator)
    Maria Q Baggstrom, MD (Sub-investigator)
    Brett Herzog, MD, PhD (Sub-investigator)
    Anjali Rohatgi, MD (Sub-investigator)
    Saiama N Waqar, MD (Sub-investigator)
    Jeffrey Ward, MD, PhD (Sub-investigator)
    Danielle Turlington, PharmD, BCOP (Sub-investigator)
    Ningying Wu, PhD (Sub-investigator)
Study leads

  • Giordano Fabricio Cittolin Santos, MD, PhD

    Principal Investigator

    Washington University School of Medicine

View source on ClinicalTrials.gov(opens in a new tab)